COVID-19 therapeutics-Reference-Cited by-同舟云学术

COVID-19 therapeutics

Published:2024-06-13 Issue:2 Volume:37 Page:
ISSN:0893-8512
Container-title:Clinical Microbiology Reviews
language:en
Short-container-title:Clin Microbiol Rev

Author:

Focosi Daniele¹^ORCID,Franchini Massimo²,Maggi Fabrizio³,Shoham Shmuel⁴^ORCID

Affiliation:

1. North-Western Tuscany Blood Bank, Pisa University Hospital, Pisa, Italy

2. Division of Hematology and Transfusion Medicine, Carlo Poma Hospital, Mantua, Italy

3. National Institute for Infectious Diseases “Lazzaro Spallanzani” IRCCS, Rome, Italy

4. Department of Medicine, Johns Hopkins University School of Medicine, Baltimore, Maryland, USA

Abstract

SUMMARY Since the emergence of COVID-19 in 2020, an unprecedented range of therapeutic options has been studied and deployed. Healthcare providers have multiple treatment approaches to choose from, but efficacy of those approaches often remains controversial or compromised by viral evolution. Uncertainties still persist regarding the best therapies for high-risk patients, and the drug pipeline is suffering fatigue and shortage of funding. In this article, we review the antiviral activity, mechanism of action, pharmacokinetics, and safety of COVID-19 antiviral therapies. Additionally, we summarize the evidence from randomized controlled trials on efficacy and safety of the various COVID-19 antivirals and discuss unmet needs which should be addressed.

Publisher

American Society for Microbiology

Link

https://journals.asm.org/doi/pdf/10.1128/cmr.00119-23

Reference362 articles.

1. Developing a direct acting, orally available antiviral agent in a pandemic: the evolution of molnupiravir as a potential treatment for COVID-19

2. Remdesivir: A Review of Its Discovery and Development Leading to Emergency Use Authorization for Treatment of COVID-19

3. The history, mechanism, and perspectives of nirmatrelvir (PF-07321332): an orally bioavailable main protease inhibitor used in combination with ritonavir to reduce COVID-19-related hospitalizations

4. Deployment of convalescent plasma for the prevention and treatment of COVID-19

5. Monoclonal antibody therapies for COVID-19: lessons learned and implications for the development of future products

Cited by 2 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Impact analysis of SARS-CoV-2 vaccination in patients treated with monoclonal antibodies: A monocentric experience;International Immunopharmacology;2024-12

2. Effect of amubarvimab-romlusevimab for treatment of severe COVID-19 in intensive care units: A retrospective cohort study;Heliyon;2024-09